Loss of HBV suppression following interferon-based HCV treatment may lead to an increase in HBV replication. A recent meta-analysis showed that 23% of coinfected patients treated with peg-IFN-α and ribavirin experienced an increase in HBV replication [5]. The risk of HBV viremia was increased in cases where the virologic response to anti-HCV therapy was sustained [5]. However, increases in HBV replication following treatment of HCV with peg-IFN-α and ribavirin are typically small [9], and severe hepatitis appears to be rare [